The idea that copper may play a role in the pathogenesis of Alzheimer’s disease is gaining momentum. Serum copper and ceruloplasmin were measured by both enzymatic (eCp) and immunologic (iCp) methods in 28 patients with Alzheimer’s disease and 29 age-matched controls. ‘‘Free copper’’ was determined by subtracting copper accounted for in the eCp assay from total serum copper. Percentage free copper, that is the proportion of serum copper not bound to ceruloplasmin, was significantly elevated in patients with Alzheimer’s compared to controls. There was significantly more ‘‘defective’’ ceruloplasmin, which is apoceruloplamin lacking its copper, in Alzheimer’s disease than in normal controls. This abnormality may precede the clinical onset of the disease and help predict risk of disease onset. Increased exposure to environmental copper (eg, the spread of copper plumbing and the use of copper in supplements) and/or defective ceruloplasmin function may play a role in the current epidemic of Alzheimer’s disease.
Squitti R., Pasqualetti P., Dal Forno G., et al. Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology. 2005;64(6):1040-1046.
2.
Squitti R., Barbati G., Rossi L., et al. Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF [beta]-amyloid, and h-tau. Neurology. 2006;67(1):76-82.
3.
Squitti R., Bressi F., Pasqualetti P., et al. Longitudinal prognostic value of serum ‘‘free’’ copper in patients with Alzheimer disease. Neurology.2009;72(1):50-55.
4.
Sparks DL, Schreurs BGTrace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2003;100(19): 11065-11069.
5.
Sparks DL, Friedland R., Petanceska S., et al. Trace copper levels in the drinking water, but not zinc or aluminum, influence CNS Alzheimer-like pathology. J Nutr Health Aging . 2006;10(4): 247-254.
6.
Deane R., Sagare A., Coma M., et al. A novel role for copper: disruption of LRP-dependent brain Abeta clearence. Presented at the Annual Meeting of the Society for Neuroscience; 2007; San Diego, CA.
7.
Morris MC, Evans DA, Tangney CC, et al. Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neurol. 2006;63(8):1085-1088.
8.
Hill GM, Brewer GJ, Juni JE, Prasad AS, Dick RDTreatment of Wilson’s disease with zinc. II. Validation of oral 64copper with copper balance. Am J Med Sci. 1986;292(6):344-349.
9.
Hung YH, Bush AI, Cherny RACopper in the brain and Alzheimer’s disease. J Biol Inorg Chem.2010;15(1):61-76.
10.
Crouch PJ, Hung LW, Adlard PA, et al. Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. Proc Natl Acad Sci U S A.2009;106(2):381-386.
11.
McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan EMClinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939-944.
12.
Morris JCThe Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.
13.
Folstein MF , Folstein SE, McHugh PR‘‘Mini-mental state.’’ A practical method for grading the cognitive state of patients for the clinician . J Psychiatr Res. 1975;12(3):189-198.
14.
Sheikh JI, Yesabage JAGeriatric Depression Scale (GDS): Recent Evidence and Development of a Shorter Version. Clinical Gerontology: A Guide to Assessment and Intervention. New York, NY: The Haworth Press; 1986.
15.
Rosen WG, Mohs RC, Davis KLA new rating scale for Alzheimer’s disease. Am J Psychiatry . 1984;141(11):1356-1364.
16.
Duke OARS.Multi-Dimensional Functional Assessment: The OARS Methodology. Durham, NC : Duke University Center for the Study of Aging and Human Development; 1978.
17.
Schosinsky KH, Lehmann HP, Beeler MFMeasurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem. 1974;20(12):1556-1563.
18.
Askari F., Innis D., Dick R., et al. Treatment of primary biliary cirrhosis with tetrathiomolybdate: results of a double blind trial. Transl Res.2010;155(3):123-130.
19.
Linder MCBiochemistry and molecular biology of copper in mammals. In: Massaro EJ, ed. Handbook of Copper Pharmacology and Toxicology. Totowa, NJ: Humana Press;2002:3-32.
20.
Arnal N., Cristalli DO, de Alaniz MJ, Marra CAClinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. Brain Res. 2010;1319:118-130.
21.
Snaedal J., Kristinsson J., Gunnarsdottir S., Olafsdottir A., Baldvinsson M., Johannesson T.Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer’s disease. A case-control study. Dement Geriatr Cogn Disord . 1998;9(5): 239-242.
22.
Squitti R., Quattrocchi CC, Salustri C., Rossini PMCeruloplasmin fragmentation is implicated in ‘free’ copper deregulation of Alzheimer’s disease. Prion. 2008;2(1):23-27.
23.
Waldman M., Lamb M.Dying for a Hamburger: Modern Meat Processing and the Epidemic of Alzheimer’s Disease. 1st US ed. New York, NY: Thomas Dune Books/St. Martin’s Press; 2005.
24.
Brewer GJ, Newsome DAToxic Copper: The Newly Discovered Culprit in Alzheimer’s Disease and Dementia. Ann Arbor, MI: George J. Brewer, Inc;2009.
25.
Wimo A., Winblad B., Aguero-Torres H., von Strauss E.The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord. 2003;17(2):63-67.
26.
White L., Petrovitch H., Ross GW, et al. Prevalence of dementia in older Japanese-American men in Hawaii: the Honolulu-Asia Aging Study. JAMA. 1996;276(12):955-960.
27.
Ueda K., Kawano H., Hasuo Y., Fujishima M.Prevalence and etiology of dementia in a Japanese community. Stroke. 1992;23(6):798-803.
28.
Grant WBDietary links to Alzheimer’s disease. Alzheimers Dis Rev. 1997;2:42-55.
29.
Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron. 2001;30(3):665-676.
30.
Ritchie CW, Bush AI, Mackinnon A., et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol. 2003;60(12):1685-1691.
31.
Wadsworth TL , Bishop JA, Domes CM, Ralle M., Brewer GJ, Quinn JFCopper complexing with tetrathiomolybdate in murine model of Alzheimer’s disease. Society for Neuroscience. 2007; Abstract 157.9.
